Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Kv1.3 inhibition as a potential microglia-targeted therapy for Alzheimer's disease: preclinical proof of concept.

Brain : a journal of neurology - 1 Feb 2018

Maezawa Izumi, Nguyen Hai M, Di Lucente Jacopo, Jenkins David Paul, Singh Vikrant, Hilt Silvia, Kim Kyoungmi, Rangaraju Srikant, Levey Allan I, Wulff Heike, Jin Lee-Way

Abstract excerpt

Microglia significantly contribute to the pathophysiology of Alzheimer's disease but an effective microglia-targeted therapeutic approach is not yet available clinically. The potassium channels Kv1.3 and Kir2.1 play important roles in regulating immune cell functions and have been implicated by in vitro studies in the 'M1-like pro-inflammatory' or 'M2-like anti-inflammatory' state of microglia, respectively. We...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Amyloid beta-Peptides
Share to Amyloid beta-Protein Precursor

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Avoidance Learning

Share to Exploratory Behavior

Share to Membrane Potentials

Share to Microglia

Share to Potassium Channel Blockers

Share to Presenilin-1

Source

Open in PubMed Open full text

Identifiers

PMID: 29272333
DOI: 10.1093/brain/awx346
PMCID: PMC5837198

Genes

APP

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Kv1.3 inhibition as a potential microglia-targeted therapy for Alzheimer's disease: preclinical proof of concept.PMID 29272333Read ↗

Unique molecular characteristics and microglial origin of Kv1.3 channel–positive brain myeloid cells in Alzheimer’s diseaseSemantic proximity Read ↗

Kv1.3 inhibition alleviates neuropathology via neuroinflammatory and resilience pathways in a mouse model of Aβ pathologySemantic proximity Read ↗

Microglia in Alzheimer's Disease: A Role for Ion ChannelsSemantic proximity Read ↗

Kv1.3 Blockade Alleviates White Matter Injury through Reshaping M1/M2 Phenotypes via the NF-κB Signaling Pathway after Intracerebral Hemorrhage.Semantic proximity Read ↗

Kv1.3 channel blockade alleviates cerebral ischemia/reperfusion injury by reshaping M1/M2 phenotypes and compromising the activation of NLRP3 inflammasome in microglia.Semantic proximity Read ↗

KCa3.1 Contributes to Neuroinflammation and Nigral Dopaminergic Neurodegeneration in Experimental models of Parkinson’s DiseaseSemantic proximity Read ↗

Kv1.3 blockade alleviates white matter injury through reshaping M1/M2 phenotypes after intracerebral hemorrhageSemantic proximity Read ↗

A Kv1.5 to Kv1.3 switch in endogenous hippocampal microglia and a role in proliferation.Semantic proximity Read ↗

Emerging therapeutic approaches targeting neuroinflammation in neurodegenerative diseasesSemantic proximity Read ↗

Turning microglia neuroprotective: Towards connexin43-specific therapy of Alzheimer’s diseaseSemantic proximity Read ↗

Dihydromyricetin inhibits microglial activation and neuroinflammation by suppressing NLRP3 inflammasome activation in APP/PS1 transgenic mice.Semantic proximity Read ↗

Microglial Drug Targets in AD: Opportunities and Challenges in Drug Discovery and DevelopmentSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.